Status:
COMPLETED
BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management
Lead Sponsor:
Eisai Inc.
Conditions:
Obesity
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess the weight loss effect of lorcaserin at the end of the first year of treatment (Week 52) and to assess the ability of lorcaserin to maintain weight loss at the e...
Eligibility Criteria
Inclusion Criteria:
- Obese adults with a BMI 30 to 45 kg/m2 or overweight adults with a BMI 27 to 29.9 kg/m2 and at least one obesity-related comorbidity (hypertension, dyslipidemia, cardiovascular disease, glucose intolerance, sleep apnea)
- Ability to complete a 2 year study
Exclusion Criteria:
- Diabetes
- Pregnancy
- History of heart valve disease
- Serious or unstable current or past medical conditions
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
3182 Patients enrolled
Trial Details
Trial ID
NCT00395135
Start Date
November 1 2006
End Date
February 1 2009
Last Update
October 2 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Arena Pharmaceuticals, Inc.
San Diego, California, United States, 92121